| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.18 | 0.0004 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.22 | 0.0004 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.27 | 0.0005 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0005 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0005 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0006 |
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | -0.73 | 0.0006 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0006 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.16 | 0.0007 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0007 |